Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SIDARTH DASARI

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1497286421
CMS profile
8920106
Location
BOULDER, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$8,792.88

241 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $6,053.88 237
Consulting Fee $2,629.00 2
Education $110.00 2

By paying entity

PY2024 · entire year · sorted by reported total

Page 4 of 5; records 151–200 of 241 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SIDARTH DASARI

NPI 1497286421 · CMS profile ID 8920106

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

BOULDER, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 5; records 151–200 of 241 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1497286421?year=2024&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SIDARTH DASARI, NPI 1497286421, CMS profile ID 8920106. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 241 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1497286421?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). SIDARTH DASARI, NPI 1497286421, CMS profile ID 8920106. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 241 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1497286421?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
SIDARTH DASARI, NPI 1497286421, CMS profile ID 8920106, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 241 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1497286421?year=2024&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

241 matching records · $8,792.88 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 241 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 241.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biogen, Inc. $26.1406/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104827970 CMS
TG Therapeutics, Inc. $21.2906/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136884336 CMS
TG Therapeutics, Inc. $7.3906/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136884342 CMS
UCB, Inc. $25.5906/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143069745 CMS
ABBVIE INC. $8.8906/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103602454 CMS
TG Therapeutics, Inc. $11.0506/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136884472 CMS
Teva Pharmaceuticals USA, Inc. $28.1406/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151704124 CMS
ABBVIE INC. $30.0606/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103602452 CMS
EMD Serono, Inc. $103.0506/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120245871 CMS
EMD Serono, Inc. $17.3206/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120218577 CMS
CATALYST PHARMACEUTICALS, INC. $18.7906/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144447902 CMS
ABBVIE INC. $7.0406/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103602450 CMS
Alexion Pharmaceuticals, Inc. $30.1206/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1094024285 CMS
Mallinckrodt Hospital Products Inc. $19.6706/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145061810 CMS
Neurocrine Biosciences, Inc. $23.8706/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150843556 CMS
Neurocrine Biosciences, Inc. $1.0506/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150892281 CMS
TG Therapeutics, Inc. $6.6906/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136884352 CMS
Novartis Pharmaceuticals Corporation $125.3606/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086812287 CMS
ABBVIE INC. $17.5505/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103602448 CMS
EMD Serono, Inc. $27.4905/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120247257 CMS
MDD US Operations, LLC $23.2405/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147770346 CMS
Lilly USA, LLC $7.6705/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135419715 CMS
UCB, Inc. $36.1105/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143069743 CMS
ANI Pharmaceuticals, Inc. $24.9605/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091151336 CMS
ABBVIE INC. $21.5505/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103602446 CMS
Grifols USA, LLC $26.4305/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124741950 CMS
TG Therapeutics, Inc. $23.2905/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136884330 CMS
ABBVIE INC. $24.7305/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103602444 CMS
PFIZER INC. $18.6705/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131730681 CMS
ABBVIE INC. $6.4405/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103602442 CMS
Amgen Inc. $19.4605/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115552651 CMS
ABBVIE INC. $9.0105/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103602440 CMS
ABBVIE INC. $5.7605/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103602438 CMS
ABBVIE INC. $5.0805/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103602436 CMS
Biogen, Inc. $28.5705/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104855674 CMS
GENZYME CORPORATION $6.5405/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139867372 CMS
Lilly USA, LLC $14.6105/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135348692 CMS
Teva Pharmaceuticals USA, Inc. $29.0305/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151704110 CMS
Alexion Pharmaceuticals, Inc. $28.1805/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093894062 CMS
Novartis Pharmaceuticals Corporation $12.7405/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086812289 CMS
PFIZER INC. $1.8605/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131732869 CMS
PFIZER INC. $5.9605/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131737973 CMS
EMD Serono, Inc. $31.5904/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120246627 CMS
ABBVIE INC. $17.2604/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103602434 CMS
JAZZ PHARMACEUTICALS INC. $21.6504/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150217931 CMS
Celgene Corporation $36.8804/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101178144 CMS
PFIZER INC. $7.4604/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131726088 CMS
Alexion Pharmaceuticals, Inc. $109.5104/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1094047499 CMS
EMD Serono, Inc. $93.7304/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120241425 CMS
Novartis Pharmaceuticals Corporation $44.4704/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086812285 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $85,700.00 2
PY2022 $402.95 15
PY2023 $3,712.55 147
PY2024 $8,792.88 241
PY2025 $38,683.91 313

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $264,897.76 21
PY2024 Principal investigator $149,030.84 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

21 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $13,043.00 12/04/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211569858
Principal investigator 1 TG Therapeutics, Inc. $30,425.00 11/30/2025 Covered Recipient Teaching Hospital
Poudre Valley Hospital
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199381
Principal investigator 1 Genentech, Inc. $8,787.00 11/06/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211569855
Principal investigator 1 TG Therapeutics, Inc. $10,650.00 11/01/2025 Covered Recipient Teaching Hospital
Poudre Valley Hospital
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199379
Principal investigator 1 Genentech, Inc. $2,328.00 10/15/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211569880
Principal investigator 1 TG Therapeutics, Inc. $18,775.00 09/30/2025 Covered Recipient Teaching Hospital
Poudre Valley Hospital
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199365
Principal investigator 1 Genentech, Inc. $3,847.00 09/19/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211569852
Principal investigator 1 Genentech, Inc. $1,632.00 09/18/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211569844
Principal investigator 1 TG Therapeutics, Inc. $4,525.00 08/31/2025 Covered Recipient Teaching Hospital
Poudre Valley Hospital
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199363
Principal investigator 1 Genentech, Inc. $2,613.00 08/21/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211569877
Principal investigator 1 Genentech, Inc. $7,842.00 08/15/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211569848
Principal investigator 1 TG Therapeutics, Inc. $16,750.00 07/31/2025 Covered Recipient Teaching Hospital
Poudre Valley Hospital
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199361
Principal investigator 1 Genentech, Inc. $2,328.00 07/21/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211569872
Principal investigator 1 Genentech, Inc. $14,244.00 06/03/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211569833
Principal investigator 1 TG Therapeutics, Inc. $9,825.00 06/01/2025 Covered Recipient Teaching Hospital
Poudre Valley Hospital
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199301
Principal investigator 1 TG Therapeutics, Inc. $8,600.00 03/31/2025 Covered Recipient Teaching Hospital
Poudre Valley Hospital
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199299
Principal investigator 1 TG Therapeutics, Inc. $12,175.00 02/28/2025 Covered Recipient Teaching Hospital
Poudre Valley Hospital
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199297
Principal investigator 1 TG Therapeutics, Inc. $10,150.00 02/01/2025 Covered Recipient Teaching Hospital
Poudre Valley Hospital
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199295
Principal investigator 1 Novartis Pharmaceuticals Corporation $8,950.67 01/30/2025 Non-covered Recipient Entity
ALPINE CLINICAL RES CTR INC
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190300263
Principal investigator 1 Novartis Pharmaceuticals Corporation $69,108.09 01/09/2025 Non-covered Recipient Entity
ALPINE CLINICAL RESEARCH CENTER
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190301801
Principal investigator 1 TG Therapeutics, Inc. $8,300.00 01/06/2025 Covered Recipient Teaching Hospital
Poudre Valley Hospital
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199293